Repurposing Hepatitis Drugs For Covid-19 Treatment
Bio Spectrum|July 2020
While researchers are still finding novel ways to cure hepatitis, the virus has shown them a new direction. HCV shares similarity with the currently prevalent SARS-CoV-2 by having a single-stranded RNA, while HBV has a double-stranded DNA as its genetic material. As a result, repurposing of existing therapies has emerged as a major area of drug development for COVID-19 and selected hepatitis drugs among others are being studied for repositioning to manage the pandemic.
Swati Shrivastava
Repurposing Hepatitis Drugs For Covid-19 Treatment

As the world celebrates Hepatitis Day on July 28, 2020, the count of people globally affected by hepatitis would be more than 325 million. Also, the count of annual average deaths by the most prevalent forms of Hepatitis- B & C (HBV and HCV) would be 1.4 million. Being one of the leading causes of death, these two viruses kill more than human immunodeficiency virus (HIV) and malaria and are responsible for two out of every three liver cancer deaths globally.

Hepatitis E virus (HEV) infection is the major cause of acute sporadic and epidemic hepatitis in India. The frequency of hepatitis C has been reported to be 1-2 per cent among voluntary blood donors and about 15-30 per cent cases of acute hepatitis in India is due to HBV.

These numbers may sound terrifying but significant progress is being made in both the prevention and treatment of the various forms of hepatitis. Vaccination is now available for both hepatitis A (HAV) and hepatitis B, and since hepatitis D (HDV) only occurs when a hepatitis B infection is present, this leaves only hepatitis C and hepatitis E in need of a vaccination for prevention.

Also, there are a number of drugs approved by U.S. Food and Drug Administration (FDA) for management of HBV and HCV infections which include interferon therapy- PEG-IFN alfa-2a, PEG- IFN alfa-2b; nucleoside and nucleotide analogues- Adefovir, Entecavir, Emtricitabine, Lamivudine, Ribavirin Telbivudine, Tenofovir; and newer direct-acting antiviral drugs (DAAs)Simeprevir, Sofosbuvir, Ledipasvir, Ombitasvir, Paritaprevir, Dasabuvir, Elbasvir and Grazoprevir, Velpatasvir

This story is from the July 2020 edition of Bio Spectrum.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the July 2020 edition of Bio Spectrum.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM BIO SPECTRUMView All
Early Diabetic Retinopathy Detection Remains a Challenge
Bio Spectrum

Early Diabetic Retinopathy Detection Remains a Challenge

The Vitreo Retinal Society of India (VRSI) and the Research Society for the Study of Diabetes in India (RSSDI) have formulated a first-of-its kind diabetic retinopathy (DR) screening guideline to help physicians and diabetologists in India educate their patients about DR.

time-read
2 mins  |
BioSpectrum India Nov 2024
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
Bio Spectrum

Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time

US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.

time-read
1 min  |
BioSpectrum India Nov 2024
Qiagen launches QIAcuityDx digital PCR system for clinical testing in oncology
Bio Spectrum

Qiagen launches QIAcuityDx digital PCR system for clinical testing in oncology

Qiagen N.V. has announced the launch of the QIAcuityDx Digital PCR System, a pivotal addition to its digital PCR portfolio now expanding into clinical diagnostics.

time-read
1 min  |
BioSpectrum India Nov 2024
Thermo Fisher introduces iCAP MX Series ICP-MS to simplify trace elemental analysis
Bio Spectrum

Thermo Fisher introduces iCAP MX Series ICP-MS to simplify trace elemental analysis

Thermo Fisher Scientific Inc. has launched the Thermo Scientific iCAP MX Series ICP-MS to simplify trace element analysis with inductively coupled plasma mass spectrometry (ICP-MS).

time-read
1 min  |
BioSpectrum India Nov 2024
Singleron, Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Bio Spectrum

Singleron, Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers

Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.

time-read
1 min  |
BioSpectrum India Nov 2024
IIT Madras identifies enhanced drug delivery method for eye treatments
Bio Spectrum

IIT Madras identifies enhanced drug delivery method for eye treatments

Researchers at the Indian Institute of Technology Madras (IIT-M) have demonstrated how drugs injected in the human eye can be better delivered to the target region through ‘convection caused by mild laser heating’.

time-read
1 min  |
BioSpectrum India Nov 2024
IIT Madras develops indigenous POCUS scanner for sports injury diagnosis
Bio Spectrum

IIT Madras develops indigenous POCUS scanner for sports injury diagnosis

A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-Care-Ultrasound (POCUS) Scanner for sports injury diagnosis and management.

time-read
1 min  |
BioSpectrum India Nov 2024
Practo strengthens Board with appointment of TVG Krishnamurthy and Dr Alexander Kuruvilla
Bio Spectrum

Practo strengthens Board with appointment of TVG Krishnamurthy and Dr Alexander Kuruvilla

Practo has appointed two new directors to its board: TVG Krishnamurthy and Dr Alexander Kuruvilla.

time-read
1 min  |
BioSpectrum India Nov 2024
Dr R N Gupta steps in as National President of Indian Pharmaceutical Association
Bio Spectrum

Dr R N Gupta steps in as National President of Indian Pharmaceutical Association

Dr R N Gupta has been elected as the National President of the Indian Pharmaceutical Association (IPA), the oldest and largest association of pharmaceutical professionals in the country, for the term 2024 - 2026 (October 1, 2024 - September 30, 2026).

time-read
1 min  |
BioSpectrum India Nov 2024
QR678 brings medtech leader Sridhar Ranganathan to advisory board
Bio Spectrum

QR678 brings medtech leader Sridhar Ranganathan to advisory board

QR678, a pioneering company dedicated to revolutionising hair and skin science through groundbreaking research and innovative solutions, has announced the appointment of Sridhar Ranganathan to its Board of Advisors.

time-read
1 min  |
BioSpectrum India Nov 2024